Results 21 to 30 of about 6,495,609 (392)

The potential of serum neurofilament as biomarker for multiple sclerosis

Brain : a journal of neurology, 2021
Multiple sclerosis is a highly heterogeneous disease, and the detection of neuroaxonal damage as well as its quantification is a critical step for patients.
S. Bittner, Jiwon Oh, E. Havrdová, M. Tintoré, F. Zipp   +4 more
semanticscholar   +1 more source

Real-World Efficacy of COVID-19 Pre-Exposure Prophylaxis with Tixagevimab/Cilgavimab in People with Multiple Sclerosis

Vaccines, 2023
Vaccines against the SARS-CoV-2 virus were authorized for use by the Food and Drug Administration (FDA) in the United States and have proven effective for the prevention of morbidity and death from COVID-19.
Luke B. Elias, Aliya Jaber, Margarita Manzano, Mark Leekoff, Andrew Sylvester, Matthew A. Tremblay   +5 more
doaj   +1 more source

Matrix Metalloproteinase-9 and Inflammation in Different Types of Multiple Sclerosis [PDF]

, 2016
Different clinical courses of multiple sclerosis, heterogeneity of its clinical implications, different effect of immunomodulatory therapy for the same clinical forms implies various pathogenetic mechanisms of central nervous system damage at this ...
Chernenko, M. (Maksym), Nehreba, T. (Tatyana), Vasylovskyy, V. (Vitaliy), Voloshyna, N. (Nataliya), Vovk, V. (Viktoriya)   +4 more
core   +2 more sources

Ofatumumab versus Teriflunomide in Multiple Sclerosis.

New England Journal of Medicine, 2020
BACKGROUND Ofatumumab, a subcutaneous anti-CD20 monoclonal antibody, selectively depletes B cells. Teriflunomide, an oral inhibitor of pyrimidine synthesis, reduces T-cell and B-cell activation.
S. Hauser, A. Bar-Or, Jeffrey A. Cohen, G. Comi, J. Correale, P. Coyle, A. Cross, J. de Seze, D. Leppert, X. Montalban, K. Selmaj, H. Wiendl, Cécile Kerloeguen, R. Willi, Bingbing Li, A. Kakarieka, Davorka Tomic, A. Goodyear, Ratnakar Pingili, D. Häring, K. Ramanathan, M. Merschhemke, L. Kappos   +22 more
semanticscholar   +1 more source

Digital Twins for Multiple Sclerosis

Frontiers in Immunology, 2021
An individualized innovative disease management is of great importance for people with multiple sclerosis (pwMS) to cope with the complexity of this chronic, multidimensional disease.
Isabel Voigt, Hernan Inojosa, Anja Dillenseger, Rocco Haase, K. Akgün, T. Ziemssen   +5 more
semanticscholar   +1 more source

Multiple sclerosis [PDF]

Global Advances in Health and Medicine, 2013
The management of multiple sclerosis (MS) is changing at a rapid rate, with the emergence of a host of new therapeutic interventions in various stages of development. Despite the enthusiasm with which the pharmaceutical industry is hailing these interventions, there remains a need for people involved in the management of MS to be circumspect regarding ...
openaire   +4 more sources

Review: ‘Gimme five’: future challenges in multiple sclerosis. ECTRIMS Lecture 2009 [PDF]

, 2010
This article is based on the ECTRIMS lecture given at the 25th ECTRIMS meeting which was held in Düsseldorf, Germany, from 9 to 12 September 2009. Five challenges have been identified: (1) safeguarding the principles of medical ethics; (2) optimizing the
Bartholomaus I., Ben-Nun A., Bennett JL, Bielekova B., Bradl M., Chabas D., De Jager PL, De Jager PL, Dornmair K., Ferguson B., Flügel A., Frischer JM, Gold R., Gregersen JW, Han MH, Hohlfeld R., Hohlfeld R., Junker A., Kerschensteiner M., Kerschensteiner M., Kinoshita M., Korn T., Krishnamoorthy G., Kuhlmann T., Kümpfel T., Kümpfel T., Kümpfel T., Lennon VA, Linington C., Lock C., Mathey EK, Misgeld T., Platten M., Pollinger B., Polman CH, Reinhard Hohlfeld, Schluesener HJ, Seitz S., Sobottka B., Stadelmann C., Trapp BD, Trapp BD, Wiendl H., Wiendl H., Zipp F.   +44 more
core   +1 more source

No Evidence of Disease Activity (NEDA) as a Clinical Assessment Tool for Multiple Sclerosis: Clinician and Patient Perspectives [Narrative Review]

Neurology and Therapy, 2023
The emergence of high-efficacy therapies for multiple sclerosis (MS), which target inflammation more effectively than traditional disease-modifying therapies, has led to a shift in MS management towards achieving the outcome assessment known as no ...
Scott D. Newsome, Cherie Binns, Ulrike W. Kaunzner, Seth Morgan, June Halper   +4 more
doaj   +1 more source

Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre [PDF]

, 2003
Background: The efficacy of interferon beta (IFN beta) is well established in relapsing-remitting multiple sclerosis (MS). However, the use of this drug in clinical practice is complex, especially because it is only partially effective, its long term ...
Dubois, B.D., Giovannoni, G., Kapoor, R., Keenan, E., Miller, D.H., Porter, B.E,, Rudge, P., Thompson, A.J.   +7 more
core   +2 more sources

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

Therapeutic Advances in Neurological Disorders, 2021
Multiple sclerosis is a complex, autoimmune-mediated disease of the central nervous system characterized by inflammatory demyelination and axonal/neuronal damage.
H. Wiendl, R. Gold, T. Berger, T. Derfuss, R. Linker, M. Mäurer, O. Aktas, K. Baum, M. Berghoff, S. Bittner, A. Chan, A. Czapliński, F. Deisenhammer, Franziska Di Pauli, R. D. Du Pasquier, C. Enzinger, E. Fertl, A. Gass, K. Gehring, C. Gobbi, N. Goebels, M. Guger, A. Haghikia, H. Hartung, F. Heidenreich, O. Hoffmann, B. Kallmann, C. Kleinschnitz, L. Klotz, V. Leussink, F. Leutmezer, V. Limmroth, J. Lünemann, A. Lutterotti, S. Meuth, U. Meyding-Lamadé, M. Plattén, P. Rieckmann, S. Schmidt, H. Tumani, F. Weber, Martin S. Weber, U. Zettl, T. Ziemssen, F. Zipp   +44 more
semanticscholar   +1 more source